LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Search

Thermo Fisher Scientific Inc

Fermé

SecteurSoins de santé

448.33 -0.08

Résumé

Variation du prix de l'action

24h

Actuel

Min

446.31

Max

448.43

Chiffres clés

By Trading Economics

Revenu

-314M

1.7B

Ventes

-1.2B

11B

P/E

Moyenne du Secteur

24.272

49.701

BPA

5.44

Rendement du dividende

0.4

Marge bénéficiaire

15.048

Employés

125,000

EBITDA

-905M

2.3B

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+35.84% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.40%

2.39%

Prochains Résultats

22 juil. 2026

Date du Prochain Dividende

15 juil. 2026

Date du Prochain Détachement de Dividende

15 juin 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-31B

164B

Ouverture précédente

448.41

Clôture précédente

448.33

Sentiment de l'Actualité

By Acuity

30%

70%

68 / 345 Classement par Healthcare

Thermo Fisher Scientific Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 avr. 2026, 13:56 UTC

Résultats

Thermo Fisher Profit Up, Warns of Inflation from Iran War -- Update

23 avr. 2026, 10:28 UTC

Résultats

Thermo Fisher Posts Higher 1Q Profit, Revenue

29 janv. 2026, 11:34 UTC

Résultats

Thermo Fisher 4Q Profit Rises as Biopharma Spending Rebounds

29 oct. 2025, 10:51 UTC

Acquisitions, Fusions, Rachats

Thermo Fisher Scientific Agrees to Buy Clario Holdings for $8.88 billion

23 oct. 2025, 20:49 UTC

Résultats

Correction to Thermo Fisher Article on Oct. 22

22 oct. 2025, 10:28 UTC

Résultats

Thermo Fisher 3Q Revenue Rises, Boosted by Life Sciences Business

15 mai 2026, 10:45 UTC

Market Talk

Contract Drug Manufacturers to Benefit From U.S. Pharma Onshoring Push -- Market Talk

23 avr. 2026, 10:01 UTC

Résultats

Thermo Fisher 1Q Organic Revenue Rose 1% >TMO

23 avr. 2026, 10:01 UTC

Résultats

Thermo Fisher: Well Positioned to Deliver Strong Year >TMO

23 avr. 2026, 10:00 UTC

Résultats

Thermo Fisher 1Q Net $1.65B >TMO

23 avr. 2026, 10:00 UTC

Résultats

Thermo Fisher 1Q Adj EPS $5.44 >TMO

23 avr. 2026, 10:00 UTC

Résultats

Thermo Fisher 1Q EPS $4.43 >TMO

23 avr. 2026, 10:00 UTC

Résultats

Thermo Fisher 1Q Rev $11.01B >TMO

24 mars 2026, 12:04 UTC

Acquisitions, Fusions, Rachats

Thermo Fisher Completes Acquisition of Clario Holdings for $8.875 Billion >TMO

24 mars 2026, 12:00 UTC

Acquisitions, Fusions, Rachats

Thermo Fisher Scientific Completes Acquisition Of Clario Holdings, Inc. >TMO

29 janv. 2026, 11:01 UTC

Résultats

Thermo Fisher 4Q Organic Revenue Rose 3% >TMO

29 janv. 2026, 11:00 UTC

Résultats

Thermo Fisher: Entering 2026 From Position of Strength >TMO

29 janv. 2026, 11:00 UTC

Résultats

Thermo Fisher 4Q Net $1.96B >TMO

29 janv. 2026, 11:00 UTC

Résultats

Thermo Fisher 4Q Rev $12.22B >TMO

29 janv. 2026, 11:00 UTC

Résultats

Thermo Fisher 4Q EPS $5.21 >TMO

29 janv. 2026, 11:00 UTC

Résultats

Thermo Fisher 4Q Adj EPS $6.57 >TMO

29 oct. 2025, 10:06 UTC

Acquisitions, Fusions, Rachats

Thermo Fisher: Clario Provides Endpoint Data Solutions for Clinical Trials >TMO

29 oct. 2025, 10:05 UTC

Acquisitions, Fusions, Rachats

Thermo Fisher: Claro Deal Includes Potential Additional Earnout, Other Payments >TMO

29 oct. 2025, 10:05 UTC

Acquisitions, Fusions, Rachats

Thermo Fisher to Buy Clario From Group Led by Astorg and Nordic Cap, Novo Holding, Cinven >TMO

29 oct. 2025, 10:04 UTC

Acquisitions, Fusions, Rachats

Thermo Fisher Scientific to Pay $8.875 Billion at Closing for Clario Holdings >TMO

29 oct. 2025, 10:00 UTC

Acquisitions, Fusions, Rachats

Thermo Fisher Scientific to Acquire Clario Holdings >TMO

22 oct. 2025, 10:01 UTC

Résultats

Thermo Fisher 3Q Organic Revenue Rose 3% >TMO

22 oct. 2025, 10:00 UTC

Résultats

Thermo Fisher: In Great Position to Deliver on 2025 Objectives >TMO

22 oct. 2025, 10:00 UTC

Résultats

Thermo Fisher 3Q Adj EPS $5.79 >TMO

22 oct. 2025, 10:00 UTC

Résultats

Thermo Fisher 3Q Rev $11.12B >TMO

Comparaison

Variation de prix

Thermo Fisher Scientific Inc prévision

Objectif de Prix

By TipRanks

35.84% hausse

Prévisions sur 12 Mois

Moyen 608.93 USD  35.84%

Haut 685 USD

Bas 490 USD

Basé sur 18 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

18 ratings

16

Achat

2

Maintien

0

Vente

Sentiment

By Acuity

68 / 345Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar
help-icon Live chat